Screener
Pacira BioSciences, Inc. PCRX Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total other (expense) income, net | (1,904) | 6,716 |
| Income before income taxes | 4,998 | 8,706 |
| Income tax expense | (2,082) | (3,894) |
| Net income | $2,916 | $4,812 |
| Net income per common share: | ||
| Basic and diluted net income per common share | $0.07 | $0.10 |
| Weighted average common shares outstanding: | ||
| Basic | 40,461 | 46,275 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s business segments — net income?
- Pacira BioSciences, Inc. (PCRX) reported business segments — net income of $2.92M in Q1 2026.
- How has Pacira BioSciences, Inc.'s business segments — net income changed year-over-year?
- Pacira BioSciences, Inc.'s business segments — net income decreased by 39.4% year-over-year, from $4.81M to $2.92M.
- What does business segments — net income mean?
- This metric represents the final bottom-line profitability of the reportable segment after all expenses, including taxes, have been deducted. It is the definitive measure of the segment's contribution to the overall company's net earnings. A positive trend indicates sustainable growth and effective management of both costs and revenues.
Ask your AI about Pacira BioSciences, Inc.'s business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude